Company profile: Vigil Neuroscience
1.1 - Company Overview
Company description
- Provider of therapeutics and programs for neurodegenerative diseases, including iluzanebart (a fully human monoclonal antibody targeting TREM2) for ALSP, an oral small molecule TREM2 agonist program for common diseases like Alzheimer's, the ILLUMINATE natural history study and IGNITE Phase 2 trial in ALSP, and the ALSPAware no-cost genetic testing and counseling program.
Products and services
- Iluzanebart (VGL101): A clinical-stage, fully human monoclonal antibody TREM2 agonist engineered to treat rare genetically defined microgliopathies, including adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)
- IGNITE Phase 2 Trial: A biomarker-driven clinical trial evaluating iluzanebart (VGL101) safety and effects on imaging and biomarkers of disease progression in subjects with ALSP
- Small Molecule TREM2 Agonist Program: An oral, IND-enabling small-molecule TREM2 agonist program architected to activate microglial function and address common neurodegenerative diseases, including Alzheimer's disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vigil Neuroscience
Emalex Biosciences
HQ: United States
Website
- Description: Provider of biotech therapies for central nervous system disorders, developing Ecopipam, a novel investigational D1 receptor dopamine blocker targeting Tourette syndrome, and conducting an FDA-regulated Phase 3 trial (EBS-101) in children, adolescents, and adults with Tourette’s. Also pursuing investigational treatments for childhood-onset fluency disorder (stuttering) in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emalex Biosciences company profile →
VistaGen Therapeutics
HQ: United States
Website
- Description: Provider of investigational biopharmaceutical therapies for CNS diseases and disorders: Fasedienol (for multiple anxiety disorders), Itruvone (for major depressive disorder and other depression-related conditions), PH80 (menopausal hot flashes, premenstrual dysphoric disorder, migraines), PH15 (to improve cognition), PH284 (appetite-related disorders, including Cachexia), AV-101 (oral prodrug targeting the NMDA receptor glycine site).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VistaGen Therapeutics company profile →
Sonoma Bio
HQ: United States
Website
- Description: Provider of Treg and Teff cell therapies and autoimmune disease research, developing adoptive Treg therapies for rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Pipeline includes SBT-77-7101, a Treg cell therapy targeting citrullinated proteins to reduce inflammation, and SBT-11-5301, a Phase 1 effector T cell-modulating biologic, with clinical trials assessing safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonoma Bio company profile →
Praxis Precision Medicines
HQ: United States
Website
- Description: Provider of genetically informed therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, translating insights from epilepsies into treatments across rare to common conditions. Offers a clinical pipeline targeting movement disorders and epilepsies, conducts the Essential3, EMBOLD, and EMBRAVE studies, and considers expanded access to investigational drugs under specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Praxis Precision Medicines company profile →
Autobahn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRβ agonist for major depressive disorder), ABX-003 (next-generation TRβ-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autobahn Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vigil Neuroscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vigil Neuroscience
2.2 - Growth funds investing in similar companies to Vigil Neuroscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vigil Neuroscience
4.2 - Public trading comparable groups for Vigil Neuroscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →